Medical Devices – Brazil Regulatory Framework
Brazil represents the biggest market for medical devices in South America. Selling and marketing medical devices in Brazil requires several actions and compliance with legislation and standards, which can be a complex process.

GENERAL BRAZILIAN RULES FOR MEDICAL DEVICES

According to the Brazilian National Agency of Health Surveillance (ANVISA), a medical device is “a healthcare product, such as equipment, devices, materials, articles, or systems for medical,  odontological, or laboratory use or application, intended for prevention, diagnosis, treatment, rehabilitation, or anticonception and that does not use pharmacological, immunological, or metabolic means to fulfill its main function in human beings, but can have its functions assisted by such means”.

Medical devices in Brazil must be registered in ANVISA, in accordance with the Brazilian Resolution RDC. No. 185. Manufacturers or importers of such products must submit to ANVISA all the documents required for the registration as well as for its maintenance, revalidation or cancellation. After evaluating all the documentation, ANVISA publishes its decision on the Brazilian Official Gazette (DOU).

The medical device company must be located in Brazil or it will need a licensed third-party company to be the Brazilian registration holder (BRH), which will hold the registration certificate title. Registration of medical devices is valid for 5 years and after that period it may be successively revalidated for the same period.

According to the risk they represent to consumers, patients, users or third parties involved, medical devices are classified as Class I, II, III or IV. In case of doubts in the classification, ANVISA is the one deciding about the classification. Class II devices have a shorter and simplified registration process (known as ‘Cadastro’), whereas Class III and Class IV need to go through a similar path but a little more complex and with some variants (known as ‘Registro’). Medical devices classified as Class III and IV need to be subjected to Brazilian GMP inspections, which are carried out by ANVISA. As an alternative, manufacturers can partake in the Medical Device Single Audit Program (MDSAP). MDSAP audit reports are accepted as a substitute for routine inspections and may be used for medical device registration in ANVISA.  Since May 2019 (RDC 270/2019), Class I medical devices only need a formal notification to ANVISA and do not need to submit to full ‘Cadastro’ approval (registration is not subject to technical review). This 2019 Resolution main goal was to help ANVISA to focus more on high-risk medical products. On the other hand, companies should make sure they have qualified regulatory team so they can ensure compliance with regulations.

The following medical devices are exempt from registration at ANVISA:

  • Medical devices intended for clinical research, when in compliance with legal provisions of the competent health surveillance authority on the performance of this activity, prohibiting such products to be commercialized and used for other purposes.
  • New presentations of a medical device set already registered and in intact individual packaging, provided that its label and instructions for use contain the information about the registration of the corresponding medical devices.
  • Accessories exclusively manufactured to be part of a medical device with a registration whose technical report has information on such accessories.

INMETRO CERTIFICATION

The National Institute of Metrology, Quality and Technology (INMETRO) is the government body responsible for the implementation of measurement, safety and quality standards for electrical and electronic products. This National Institute is in charge of the notification of proposed technical regulations to the World Trade Organization (WTO) and acts as the national enquiry point under the WTO Agreement on Technical Barriers to Trade (TBT). It guides the activities of accreditation, inspection, testing and certification bodies in Brazil. A broad range of products require INMETRO certification accompanied by inspection, including medical devices (electromedical, regardless of their class).

INMETRO certification (conducted in an INMETRO-certified testing laboratory) must be done prior to ANVISA approval, as it is part of the medical product’s technical documentation required for submission. A product that is certified by an INMETRO-accredited Certification Body ensures that such product is compliant with Brazilian regulations and required safety standards. INMETRO certification is valid for 5 years and may be renewed for additional 5.

Placing and marketing a medical device in Brazil market can be a tough task. With an experienced team located both in the EU and Brazil, Critical Catalyst is available to assist your company in any part of the process, making it easier and assuring compliance with the applicable regulatory requirements.

References:

  1. Ministério da Saúde, Agência Nacional de Vigilância Sanitária (ANVISA) – Resolução da Diretoria Colegiada – RDC No. 185, de 22 de Outubro de 2001.
  2. Ministério da Saúde, Agência Nacional de Vigilância Sanitária (ANVISA) – Resolução da Diretoria Colegiada – RDC Nº 27, de 21 de Junho de 2011.
  3. Ministério da Saúde, Agência Nacional de Vigilância Sanitária (ANVISA) – Resolução da Diretoria Colegiada – RDC Nº 270, de 28 de Fevereiro de 2019.
  4. Ministério do Desenvolvimento, Indústria e Comércio Exterior, Instituto Nacional de Metrologia, Normalização e Qualidade Industrial-INMETRO – Portaria nº 350, de 06 de setembro de 2010.

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »